Chiesi Farmaceutici Implements Cegedim Relationship Management Mobile Intelligence(TM) Software as a Service (SaaS) CRM Solution

Mobile Intelligence Delivers Unparalleled Flexibility, Robust Functionality and Intuitive Graphical User Interface (GUI) to Primary Care, Specialty and Over-the-Counter (OTC) Commercial Teams in Spain

PARIS, Oct 11, 2011 (BUSINESS WIRE) -- Cegedim Relationship Management today announced that Chiesi Farmaceutici Spain will upgrade its CRM Solution to the next generation Mobile Intelligence SaaS CRM Solution. Chiesi is a global life sciences company and is a forerunner in the therapeutic areas of respiratory, cardiovascular and special care diseases. Cegedim Relationship Management is the world's leading provider of Life Sciences-specific CRM solutions and maintains the position of global market share leader of pharmaceutical CRM.

Multi-tenant SaaS, Tailor-fit for Life Sciences

Pharmaceutical commercial teams demand a flexible, mobile, and industry-specific CRM solution to maximize their productivity and effectiveness in building relationships with stakeholders. The solution must be fast and have an intuitive yet consistent GUI online and/or offline.

Cegedim Relationship Management's leading MobiIe Intelligence SaaS CRM solution will be seamlessly configured and deployed across Chiesi's Primary, Specialty and OTC commercial teams throughout Spain. Mobile Intelligence's flexible and robust functionality will enable Chiesi to fully adapt the solution as their business needs grow.

"Our industry's evolution required us to find the most flexible and proven solution to enable stakeholder interaction. Upgrading to Mobile Intelligence will help us manage our stakeholders' varying and evolving needs while enabling us to build closer relationships with them," said Rosa Irizar, Business Support Director, Chiesi Spain. "The aspects of Mobile Intelligence that made it stand apart from competitors are that it maintains the same capabilities and user interface both online and offline, and also has the possibility to add new modules according to growth of our needs."

In addition to Mobile Intelligence, Chiesi will utilize OneKey(TM), the most comprehensive worldwide healthcare database dedicated to the Life Sciences industry.

"We are delighted to continue to strengthen our relationships with our existing customers through upgrades. Mobile Intelligence provides an answer to the transformed life sciences industry that clients can trust," said Laurent Labrune, Chief Executive Officer of Cegedim Relationship Management. "Our ability to assess global CRM issues and provide clients with flexible industry-specific solutions separates us from the competition."

About Cegedim Relationship Management

Cegedim Relationship Management is the Life Sciences industry's leading provider of Customer Relationship Management (CRM) solutions. Designed specifically for Life Sciences, the company's innovative business solutions incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Relationship Management enables more than 200,000 users in many of the world's most innovative companies to stay ahead of market challenges. In addition to CRM, Cegedim Relationship Management also provides marketing, data optimization and regulatory compliance solutions in more than 80 countries. Cegedim Relationship Management is part of the France-based Cegedim S.A. Group.

www.cegedim.com/rm           

About Cegedim

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,500 people in more than 80 countries and generated revenue of EUR 927 million in 2010. Cegedim SA is listed in Paris

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…